Evgen Pharma (EVG) Reaches New 12-Month Low at $12.53
Evgen Pharma PLC (LON:EVG)’s share price hit a new 52-week low during mid-day trading on Friday . The company traded as low as GBX 12.53 ($0.17) and last traded at GBX 14.25 ($0.19), with a volume of 519611 shares. The stock had previously closed at GBX 14.25 ($0.19).
A number of equities analysts have issued reports on EVG shares. Beaufort Securities reiterated a “speculative buy” rating on shares of Evgen Pharma in a research report on Thursday, October 5th. Northland Securities restated a “buy” rating and issued a GBX 97 ($1.31) target price on shares of Evgen Pharma in a research report on Wednesday, October 4th.
About Evgen Pharma
Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane.
Receive News & Ratings for Evgen Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.